Combination Drug Approved for High Blood Pressure

Tribenzor sanctioned for those who don't respond to other drugs

Related Encyclopedia • Acidophilus • Antioxidants • Caffeine (and its effects) • Calcinosis More... Related Animations • Animation: What is Hypertension? More... Related Healthscout Videos Stay Flu-Free Forever Pumpkin and Cream Cheese Wontons Holiday Foods: Eat This, Not That Anaconda: Beating a Silent Killer More... Related Drug Information • Klor-Con • Klor-Con ER More... Related News Articles • Binge Eating May Be a High All Its Own • Health Tip: Regain Weight the Healthy Way • Experts Issue Guidelines on Safe Weight Loss for Athletes • Dads Can Light Their Grills Without Fear More...

MONDAY, July 26 (HealthDay News) -- Tribenzor, a three-in-one drug to treat high blood pressure, has been approved by the U.S. Food and Drug Administration.

Tribenzor combines amlodipine, marketed by Pfizer as Norvasc, olmesartan medoxomil, marketed by Daiichi Sankyo as Benicar, and a third drug, hydrochlorothiazide. The combination medication was approved for people whose high blood pressure isn't well controlled on other combinations of anti-hypertension drugs.

Text Continues Below

---

Daiichi Sankyo, based in Japan with U.S. headquarters in Parsippany, N.J., produces the newly approved drug.

In a news release, the company said adverse reactions to once-daily Tribenzor could include dizziness, swelling, headache, fatigue, muscle spasms, nausea, diarrhea or infections of the respiratory or urinary tracts.

More information

To learn more about high blood pressure, visit the U.S. National Heart Lung and Blood Institute.

-- Scott Roberts